Close

BeiGene (BGNE) Approved in China to Conduct BGB-A317 Clinical Trials

September 12, 2016 6:23 AM EDT Send to a Friend
BeiGene, Ltd. (Nasdaq: BGNE) announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login